United Kingdom

Cleveland Biolabs Inc (CBLI.OQ)

CBLI.OQ on NASDAQ Stock Exchange Capital Market

20 Feb 2018
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Cleveland BioLabs reports Q3 ‍net loss per share, excluding minority interests, $0.11
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Cleveland BioLabs Inc :Cleveland BioLabs reports third quarter 2017 financial results and development progress.Q3 revenue $300,000 versus $1.1 million.Cleveland BioLabs Inc - qtrly ‍net loss, excluding minority interests, $0.11 per share​.Cleveland BioLabs -current cash,cash equivalents,short-term investments is expected to fund operations for at least 1 year beyond filing date of form 10-Q​.  Full Article

Cleveland Biolabs quarterly loss per share $0.17
Monday, 15 Aug 2016 

Cleveland Biolabs Inc :Quarterly loss per share $0.17.  Full Article

Cleveland Biolabs posts a loss of $0.06 per share in Q1
Monday, 16 May 2016 

Cleveland Biolabs Inc : Cleveland Biolabs reports first quarter 2016 financial results and development progress . Q1 loss per share $0.06 .Q1 revenue $800,000 versus $600,000.  Full Article

Cleveland Biolabs and CFO Neil Lyons agreed on Lyon's termination of employment
Friday, 6 May 2016 

Cleveland Biolabs Inc : Co, Neil Lyons, Co's CFO mutually agreed that Lyons would terminate his employment with company effective May 6, 2016 .Lyons to become a consultant; in his role as a consultant, Lyons will continue to serve as CFO of company.  Full Article

N.Korea threats spur U.S. search for new radiation therapies

Jan 31 The escalating threat of a potential nuclear war between North Korea and the United States has led the Department of Defense to join hands with a clutch of companies in developing more effective medical treatments for acute radiation syndrome.